Aurobindo Pharma incorporates Avogent Lifesciences for manufacturing and marketing
- Aurobindo Pharma incorporated Avogent Lifesciences Private Limited on August 31, 2026
- The entity is a wholly owned subsidiary of Apitoria Pharma Private Limited
- Initial share capital is ₹5 crore divided into 50,00,000 equity shares
- The subsidiary will handle manufacturing and marketing operations in India and abroad
- No regulatory approvals were required for the incorporation
*this image is generated using AI for illustrative purposes only.
Aurobindo Pharma has incorporated a new subsidiary, Avogent Lifesciences Private Limited, to undertake manufacturing and marketing operations in India and foreign countries.
The entity was incorporated on August 31, 2026, with an initial share capital of ₹5 crore. It is structured as a wholly owned subsidiary of Apitoria Pharma Private Limited, which is itself a wholly owned subsidiary of Aurobindo Pharma.
Subsidiary incorporation details
The new entity falls under the pharmaceuticals industry. The disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Key details of the new subsidiary are summarised below:
| Parameter | Details |
|---|---|
| Subsidiary name | Avogent Lifesciences Private Limited |
| Parent entity | Apitoria Pharma Private Limited |
| Initial capital | ₹5 crore |
| Share structure | 50,00,000 equity shares of ₹10 each |
| Purpose | Manufacturing and marketing in India and abroad |
| Regulatory approvals required | None |
The promoters and promoter group of Aurobindo Pharma have no interest in the transaction. The company stated that no governmental or regulatory approvals were required for the incorporation.
Historical Stock Returns for Aurobindo Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.26% | +5.43% | +7.28% | +38.91% | +64.93% | +133.10% |
How does the creation of Avogent Lifesciences align with Aurobindo Pharma's strategic focus on specific therapeutic areas or generic drug segments?
What is the expected timeline for Avogent Lifesciences to achieve operational profitability and break-even?
Which key international markets are prioritized for the initial marketing and distribution efforts of the new subsidiary?
16
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
